奧園健康(03662.HK)擬不超6.91億元收購醫美公司浙江連天美企業55%股權
格隆匯9月18日丨奧園健康(03662.HK)公告，於2020年9月18日，買方廣東欣粵容產業投資有限公司（公司間接全資附屬公司）與賣方廣州盛粧醫療美容投資有限公司就收購事項訂立買賣協議，買方已有條件同意收購目標公司浙江連天美企業管理有限公司的55%股權，現金代價上限為人民幣6.91億元。
目標公司為一間於中國註冊成立的有限公司，而目標集團主要於中國從事提供醫美服務業務。於本公告日期，賣方及買方分別持有目標公司的55%及5%股權。
公司表示，目標集團為中國領先的醫美綜合服務集團，提供醫美行業的綜合服務，包括美容手術服務、微創美容服務及美容皮膚服務。其目前於中國經營兩傢俬人醫美醫院，即杭州華山連天美醫療美容醫院及杭州維多利亞醫療美容醫院，該兩家醫院的總營運面積為約30,000平方米，均獲授予5A級管理標準並擁有標準醫療機構營運資質（其中包括由杭州華山連天美醫療美容醫院取得的四級（高難度）手術資質）。
截至本公告日期，目標集團擁有合共24項註冊專利，其中一項與下頜角有關的註冊專利於參與整形專利國際巡展（韓國站）期間獲韓國知識產權局授予發明專利。作為對其強大的技術能力、行業領先品牌及競爭力的認可，目標集團榮獲60多項獎項及榮譽，並擁有逾300,000名客户。受益於中國醫美市場的快速增長及憑藉其知名品牌聲譽以及累積逾35年豐富行業經驗及專業知識，目標公司已成為中國浙江省醫美行業的龍頭企業。
董事認為收購事項乃集團進一步發展醫美業務及拓闊及多元化收入來源的良機，此與集團補充其物業管理服務及商業運營服務的發展策略一致。此外，董事一直積極物色合適的投資機遇以為股東實現更佳的回報。監於目標集團的品牌聲譽及經營業績，公司認為收購事項將進一步促成集團與目標集團間的戰略合作並提升現有協同效益，從而推動集團的業務增長及增強集團的盈利能力，進而提升股東回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
